Investors
Investor
Presentation
Most of the human population will require corrective lenses within their lifetime. As the natural lens deteriorates with age it will require more permanent, enduring solutions.
Ocumetics is in the process of developing advanced lens technologies that are designed to address issues of accommodation in the human eye, allowing near, intermediate, and distance range of vision, without lag, and as natural as the human eye.
Our goal is to enhance lives and change the way people see and experience the world around them!
Press Releases
- September 18, 2023 - Ocumetics Continues to Meet Significant Development Milestones
- September 1, 2023 - Ocumetics Welcomes Dr. Doyle Stulting and Dr. Bart McRoberts to Board of Directors
- August 15, 2023 - Ocumetics Announces Completion of Unit Private Placement
- July 31, 2023 - Ocumetics Notice of Meeting
- July 31, 2023 - Ocumetics Management Information Circular
- July 31, 2023 - Ocumetics Form of Proxy Aug 25, 2023 AGM
- July 25, 2023 - Ocumetics Announces Completion of First Tranche of Unit Private Placement
- June 22, 2023 - Ocumetics Announces Private Placement
- June 20, 2023 - Ocumetics Announces Commencement of Biocompatibility and Animal Studies for Updated Lens Design
- June 12, 2023 - Ocumetics Announces Appointment of President and CEO
- June 2, 2023 - Ocumetics Announces Issuance of Shares
- Apr 24, 2023 - Ocumetics Announces Corporate Changes
- Apr 19, 2023 - Ocumetics Announces Design Lockdown
- Mar 03, 2023 - Ocumetics Announces Advertising Campaign with Investing News Network
- Feb 13, 2023 - Ocumetics Announces Successful Completion of Animal Studies
- Feb 01, 2023 - Ocumetics Announces Completion of Unit Private Placement
- November 8, 2022 - Ocumetics Announces Intent to Use Existing Shareholder Exemptions
- October 19, 2022 - Ocumetics Announces Private Placement
- October 11, 2022 - Ocumetics Announces Appointment of Medical Advisory Board
- September 12, 2022 - Ocumetics Announces Listing on the OTC QB Market
- August 29, 2022 - Ocumetics' lens technology delivers 14-diopters of accommodation
- August 17, 2022 - Ocumetics Announces Frankfurt Stock Exchange Listing
- May 24, 2022 - Ocumetics' Lens Technology Delivers 12-Diopters of Accomodation in Bench Tests
- May 18, 2022 - Ocumetics Technology Corp. provides update on preclinical studies
- Feb 15, 2022 - Ocumetics engages intraocular lens product and marketing expert
- Feb 3, 2022 - Ocumetics Announces Commencement of Regulatory Strategy Project with Clinical Research Consultants, Inc.
- Jan 17, 2022 - Ocumentics Technology Corp. Partners with Female-Led Bioana
- Jan 10, 2022 - Ocumetics Techmology Corp. provides update on preclinical studies
- Nov 24, 2021 - Ocumetics Announces Issuance of Stock Options
- October 26, 2021 - Ocumetics commences preclinical studies for the Bionic Lens
- October 18, 2021 - Ocumetics Announces Appointment of Dr. Doyle Stulting as Chief Medical Officer
- October 1, 2021 - Ocumetics Announces Director and Officer Changes
- August 31, 2021 - Ocumetics Announces Completion of Qualifying Transaction
- July 23, 2021 - Ocumetics Announces Conditional Approval of Qualifying Transaction with Ocumetics Technology Corp. and Filing of Filing Statement
stock info
stock quote
stock chart
financial
annual financial information
interim financial information
Year Ending December 31, 2023
Year Ending December 31, 2022
Five Months Ending December 31, 2021
Sign Up
We’ll keep you up to date on investor news and our clinical trials.